Brokerages Set $11.38 Price Target for Harrow Health (NASDAQ:HROW)

Shares of Harrow Health (NASDAQ:HROW) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokers have set a 1-year consensus target price of $11.38 for the company and are forecasting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Harrow Health an industry rank of 99 out of 256 based on the ratings given to its competitors.

Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Harrow Health from a “buy” rating to a “hold” rating in a report on Wednesday, May 15th. ValuEngine upgraded shares of Harrow Health from a “sell” rating to a “hold” rating in a report on Monday, May 13th. Finally, TheStreet upgraded shares of Harrow Health from a “d-” rating to a “c” rating in a report on Wednesday, May 1st.

In related news, Director Robert J. Kammer sold 10,000 shares of Harrow Health stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $4.57, for a total value of $45,700.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 30,000 shares of company stock worth $151,200 in the last quarter. Insiders own 12.43% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Trexquant Investment LP bought a new position in shares of Harrow Health during the 1st quarter worth about $77,000. Jane Street Group LLC bought a new position in shares of Harrow Health during the 1st quarter worth about $87,000. Citigroup Inc. bought a new position in shares of Harrow Health during the 1st quarter worth about $92,000. FineMark National Bank & Trust bought a new position in shares of Harrow Health during the 1st quarter worth about $113,000. Finally, BlueCrest Capital Management Ltd bought a new position in shares of Harrow Health during the 1st quarter worth about $125,000. Institutional investors own 32.15% of the company’s stock.

Shares of NASDAQ HROW traded down $0.14 during mid-day trading on Monday, reaching $5.62. 302,900 shares of the company traded hands, compared to its average volume of 251,941. Harrow Health has a fifty-two week low of $1.99 and a fifty-two week high of $7.20. The company has a debt-to-equity ratio of 0.47, a current ratio of 3.43 and a quick ratio of 3.22. The firm has a market capitalization of $146.22 million, a PE ratio of 9.21 and a beta of -0.29.

Harrow Health (NASDAQ:HROW) last posted its quarterly earnings data on Tuesday, March 12th. The company reported $0.77 EPS for the quarter, missing the Zacks’ consensus estimate of $0.84 by ($0.07). The company had revenue of $11.38 million for the quarter, compared to analyst estimates of $10.92 million. Harrow Health had a net margin of 65.84% and a return on equity of 100.84%. Sell-side analysts anticipate that Harrow Health will post -0.1 earnings per share for the current fiscal year.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Further Reading: Using other technical indicators with support levels

Get a free copy of the Zacks research report on Harrow Health (HROW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.